EUVIMEDEUVIMED entdecken
Crossref

Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis

Britt Roosenboom iD, Peter J Wahab, Carolijn Smids, Jos Meijer, Larissa G J M Kemperman, Marcel J M Groenen, Ellen G van Lochem, Carmen S Horjus Talabur Horje

Inflammatory Bowel Diseases · 03.06.2024 · 30 (6) · 930-938

DOI: 10.1093/ibd/izad123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.07.2023. Verfasst von Britt Roosenboom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, the Netherlands. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Integrins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic strategies for patients with ulcerative colitis (UC) are based on patient- and disease-related factors in combination with drug characteristics but fail to predict success in individual patients. A considerable proportion of UC patients do not respond to the biological vedolizumab. Therefore, pretreatment biomarkers for therapeutic efficacy are urgently needed. Mucosal markers related to the integrin-dependent T lymphocyte homing could be potent predictors.

Methods

We prospectively included 21 biological- and steroid-naive UC patients with moderate-to-severe disease activity planned to escalate therapy to vedolizumab. At week 0, before initiating treatment, colonic biopsy specimens were obtained for immunophenotyping and immunohistochemistry. Clinical and endoscopic disease activity were determined at week 16 after 4 infusions of vedolizumab. In addition, we retrospectively included 5 UC patients who were first treated with anti-tumor necrosis factor α before receiving vedolizumab to compare with biological-naive patients.

Results

Abundance of α4β7 on more than 8% of all CD3+ T lymphocytes in colonic biopsies at baseline was predictive for responsiveness to vedolizumab (sensitivity 100%, specificity 100%). The threshold for the proportion of MAdCAM-1+ and PNAd+ of all venules in the biopsies predictive for responsiveness to vedolizumab was ≥2.59% (sensitivity 89%, specificity 100%) and ≥2.41% (sensitivity 61%, specificity 50%), respectively. At week 16, a significant decrease of α4β7+CD3+T lymphocytes was demonstrated in responders (18% [12%-24%] to 8% [3%-9%]; P = .002), while no difference was seen in nonresponders (4% [3%-6%] to 3%; P = .59).

Conclusions

UC responders to vedolizumab have a higher percentage of α4β7+CD3+ T lymphocytes and a higher proportion of MAdCAM-1+ venules in colonic biopsies than nonresponders before initiating therapy. Both analyses could be promising predictive biomarkers for therapeutic response and may lead to more patient tailored treatment in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAntibodies, Monoclonal, HumanizedGastrointestinal AgentsIntegrinsMucoproteinsIntestinal MucosaCell Adhesion MoleculesHumansMaleFemaleAdultMiddle AgedProspective StudiesVenulesRetrospective StudiesBiomarkersImmunoglobulinsYoung AdultPrognosisT-LymphocytesFollow-Up StudiesColonAged

Stichwörter der Autor:innen

IBDT cell homingvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, Humanizedintegrin alpha4beta7MADCAM1 protein, humanGastrointestinal AgentsIntegrinsMucoproteinsCell Adhesion MoleculesBiomarkersImmunoglobulins

Autor:innen und Institutionen

  • Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, the Netherlands.
  • Department of Pathology, Rijnstate Hospital, Arnhem, the Netherlands.
  • Department of Microbiology and Immunology, Rijnstate Hospital, Arnhem, the Netherlands.

ORCID-Profile: Britt Roosenboom

Zitieren

APA

Roosenboom, B., Wahab, P. J., Smids, C., Meijer, J., Kemperman, L. G. J. M., Groenen, M. J. M., van Lochem, E. G., & Horjus Talabur Horje, C. S. (2024). Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis. Inflammatory Bowel Diseases, 30(6), 930-938. https://doi.org/10.1093/ibd/izad123

Vancouver

Roosenboom B, Wahab PJ, Smids C, Meijer J, Kemperman LGJM, Groenen MJM, et al. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis. Inflammatory Bowel Diseases. 2024;30(6):930-938. doi:10.1093/ibd/izad123

BibTeX
@article{Roosenboom2024,
  author = {Roosenboom, Britt and Wahab, Peter J and Smids, Carolijn and Meijer, Jos and Kemperman, Larissa G J M and Groenen, Marcel J M and van Lochem, Ellen G and Horjus Talabur Horje, Carmen S},
  title = {Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {6},
  pages = {930--938},
  doi = {10.1093/ibd/izad123}
}
Kostenlos starten →